Close Menu

FISH

The test MRSA and MSSA directly from blood culture samples in about one hour, compared to between 48 and 72 hours with other methods, the company said. 

In Nature this week: a fluorescence in situ hybridization-based method for multiplex RNA imaging, benchmark dataset for structural variants, and more.

A new microbiome analysis uncovered cancer type-specific bacterial community features, along with intracellular bacteria in tumor and associated immune cells.

The approval was based on data showing superior efficacy for Alunbrig compared to Pfizer's Xalkori, especially in patients with brain metastasis.

Integrated analyses uncovered recurrent changes in renal medullary carcinoma, including potential treatment vulnerabilities stemming from DNA replication stress.

The firm, cofounded by several Harvard University researchers, is commercializing a single-cell spatial transcriptomics technology called MERFISH. 

The team will present the results to the US Food and Drug Administration as part of a 510(k) application in order to commercialize the technology with Biofluidica.

The data add to growing evidence supporting the use of HER2 therapy across solid tumors, though researchers find a difficult path to a tissue-agnostic approval.

The TATTON study found a combination therapy could treat some EGFR-positive lung cancer patients who developed MET-based resistance, but the best way to gauge MET status isn't yet clear.

The company said that diagnostic testing volumes, product and royalty revenues, and clinical services revenues all fell year over year.

Pages

Researchers have developed a robotic lab assistant, the Verge reports.

CBC News reports Canada's Supreme Court is to rule on the constitutionality of the country's genetic non-discrimination law today.

The Associated Press reports the World Health Organization is sending experts to China to investigate the animal source of SARS-CoV-2.

In Science this week: atlas of affected cell populations in idiopathic pulmonary fibrosis, and more.